The rollercoaster ride that led to Dynavax stock skyrocketing 74%

Dynavax Technologies Corp. shares surged 74% in extremely heavy morning trade Monday after a Food and Drug Administration advisory committee voted in favor of its hepatitis B vaccine.

The company DVAX, +74.38% also got a thumbs-up from Wall Street, with analysts at J.P. Morgan and RBC Capital Markets upgrading the company and hiking their price targets to $27 and $26 respectively.

Though the FDA itself has not yet released its approval decision, the Friday vote comes as a major vote of confidence in Dynavax’s vaccine following questions from regulators about safety.

The news also comes as a possible tipping point for the company after years of uncertainty.

>>> Original Source <<<